Literature DB >> 14707282

MDM2, an introduction.

Tomoo Iwakuma1, Guillermina Lozano.   

Abstract

The murine double minute 2 (mdm2) gene encodes a negative regulator of the p53 tumor suppressor. Amplification of mdm2 or increased expression by unknown mechanisms occurs in many tumors. Thus, increased levels of MDM2 would inactivate the apoptotic and cell cycle arrest functions of p53, as do deletion or mutation of p53, common events in the genesis of many kinds of tumors. MDM2 functions as an E3 ubiquitin ligase to degrade p53. MDM2 also binds another tumor suppressor, ARF. This interaction sequesters MDM2 in the nucleolus away from p53, thus activating p53. Many additional MDM2 interacting proteins have been identified. Functions of MDM2 independent of p53 have also been identified. This article is an introduction to MDM2, its structure and biological functions, as well as its relationship to its binding partners.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14707282

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  144 in total

1.  AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis.

Authors:  Haitao Ji; Zhiyong Ding; David Hawke; Dongming Xing; Bing-Hua Jiang; Gordon B Mills; Zhimin Lu
Journal:  EMBO Rep       Date:  2012-06-01       Impact factor: 8.807

2.  Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.

Authors:  Shunbin Xiong; Vinod Pant; Young-Ah Suh; Carolyn S Van Pelt; Yongxing Wang; Yasmine A Valentin-Vega; Sean M Post; Guillermina Lozano
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

3.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Authors:  Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth L Bond; David G Johnson; Arnold J Levine; Guillermina Lozano
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

4.  Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells.

Authors:  Diarmuid M Moran; Carl G Maki
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

5.  HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication.

Authors:  Taisuke Izumi; Katsuhiro Io; Masashi Matsui; Kotaro Shirakawa; Masanobu Shinohara; Yuya Nagai; Masahiro Kawahara; Masayuki Kobayashi; Hiroshi Kondoh; Naoko Misawa; Yoshio Koyanagi; Takashi Uchiyama; Akifumi Takaori-Kondo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-11       Impact factor: 11.205

6.  Association of Murine Double Minute 2 Genotypes and Lung Cancer Risk.

Authors:  Yu-Chao Lin; Wen-Shin Chang; Te-Chun Shen; Hsin-Ting Li; Chia-Hsiang Li; Yu-Chen Hsiau; Yun-Chi Wang; Cheng-Nan Wu; Chi-Li Gong; Zhi-Hong Wang; Chia-Wen Tsai; Te-Chun Hsia; DA-Tian Bau
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

7.  Oncogenic STRAP functions as a novel negative regulator of E-cadherin and p21(Cip1) by modulating the transcription factor Sp1.

Authors:  Lin Jin; Pran K Datta
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

Authors:  Maria Maguire; Paul C Nield; Timothy Devling; Rosalind E Jenkins; B Kevin Park; Radoslaw Polański; Nikolina Vlatković; Mark T Boyd
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 9.  MdmX regulates transformation and chromosomal stability in p53-deficient cells.

Authors:  Zdenka Matijasevic; Anna Krzywicka-Racka; Greenfield Sluder; Stephen N Jones
Journal:  Cell Cycle       Date:  2008-10-15       Impact factor: 4.534

10.  Mdm2 and Mdm4 loss regulates distinct p53 activities.

Authors:  Juan A Barboza; Tomoo Iwakuma; Tamara Terzian; Adel K El-Naggar; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.